This article is more than 5 years old. Information may no longer be current.
VIDEO: Expert discusses use of lithoplasty device for calcium in femoropopliteal arteries
LAS VEGAS — In this video, Thomas Zeller, MD, PhD, highlights new data from the DISRUPT PAD study that evaluated use of a lithoplasty device in patients with symptomatic calcified femoropopliteal lesions.
“The 6-month outcomes [were eagerly] awaited by the physician community. Calcium is the main enemy of each kind of interventional treatment in the femoropopliteal vessel segment,” Zeller, head physician in the department of angiology at Universitäts Herzzentrum, Bad Krozingen, Germany, said.
Among the results discussed, mean net lumen gain was 3 mm, only one patient required a stent, additional pre- or post-dilatation was performed in 20% of cases, primary patency was 77% at 6 months and the rate of freedom from target lesion revascularization was high.
Twelve-month follow-up data are anticipated, Zeller said.
“In my opinion, lithoplasty will not remain a standalone treatment option for calcium; [it] might be an adjunct to drug-eluting balloons or drug-eluting stents in the future,” he said.